$$$MEGA-NEWS BEI GENEREX$$$ - 500 Beiträge pro Seite
eröffnet am 17.05.06 14:17:59 von
neuester Beitrag 17.05.06 15:10:54 von
neuester Beitrag 17.05.06 15:10:54 von
Beiträge: 3
ID: 1.060.677
ID: 1.060.677
Aufrufe heute: 0
Gesamt: 1.132
Gesamt: 1.132
Aktive User: 0
ISIN: US3714853013 · WKN: A2DL9M
0,0470
EUR
+0,86 %
+0,0004 EUR
Letzter Kurs 21.02.22 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4000 | +49,07 | |
| 2,1000 | +33,76 | |
| 4,0600 | +27,67 | |
| 1,6400 | +25,19 | |
| 26,45 | +23,02 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,5000 | -28,30 | |
| 2,6120 | -32,37 | |
| 0,6864 | -32,57 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 |
Feedback
Es geht vorbörslich bereits um 5% nach oben!
Der Rebound hat wie angekündigt begonnen!
Generex Oral-lyn(TM) Diabetes Treatment Paradigm to Be Presented at Ecuadorian Scientific Symposium
Generex Oral-lyn Available for Commercial Sale in Ecuador for the Treatment of Type-1 and Type-2 Diabetes
Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today that Dr. Jaime Guevara-Aguirre, M.D., of the Institute of Endocrinology IEMYR in Quito, Ecuador and an independent Principal Investigator in respect of many of the Company's clinical trials, will present the Generex Oral-lyn™ diabetes treatment paradigm at the 8th Ecuadorian Endocrinology Congress being held in Cuenca, Ecuador, May 17-19, 2006. Generex Oral-lyn, the Company's proprietary oral insulin spray product, is currently manufactured and available for commercial sale in Ecuador for the treatment of Type-1 and Type-2 diabetes.
Generex Oral-lyn is a safe, simple, fast, effective, and pain-free alternative to subcutaneous injections of prandial insulin. Human regular insulin in the Generex Oral-lyn liquid spray product is conveniently delivered to the membranes of the oral cavity by a simple asthma-like device with no pulmonary (lung) deposition. Dr. Guevara will describe how Generex Oral-lyn can play a vital role as an interventional pharmacologic agent to delay the onset or progression of diabetes and the complications associated with diabetes. The prospect of more precise blood glucose control offered by Generex Oral-lyn will give physicians a greater opportunity to satisfy "treat to target" benchmarks identified by the American Diabetes Association and similar organizations.
The Congress brings together more than 300 endocrinologists, diabetologists, internists, general medical practitioners, and nurses in the field of endocrinology including diabetes and pediatric and adolescent endocrinology, and includes participation by scientific opinion leaders from Ecuador, Argentina, Columbia, Chile, the United States, Mexico, and Uruguay. Participating companies include GlaxoSmithKline, Merck, Roche, and Eli Lilly.
The Congress is another opportunity for Generex and its Latin American joint venture partner, PharmaBRAND, S.A. (www.pharmabrand.com.ec), to showcase Generex Oral-lyn and to increase awareness in the local medical community about the use and benefits of this novel insulin delivery system. Generex Oral-lyn has been approved by the Ecuadorian Ministry of Public Health for the treatment of patients with Type-1 and Type-2 diabetes mellitus.
Generex Oral-lyn will be featured at PharmaBRAND's presentation booth at the Congress where sales agents, promotional materials, and the Generex Oral-lyn monograph will be available. In addition, in the evening of May 17, 2006, PharmaBRAND will host a Congress-related dinner for more than 40 members of The Endocrine Society of Ecuador at which the Generex Oral-lyn monograph will be distributed.
Der Rebound hat wie angekündigt begonnen!
Generex Oral-lyn(TM) Diabetes Treatment Paradigm to Be Presented at Ecuadorian Scientific Symposium
Generex Oral-lyn Available for Commercial Sale in Ecuador for the Treatment of Type-1 and Type-2 Diabetes
Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today that Dr. Jaime Guevara-Aguirre, M.D., of the Institute of Endocrinology IEMYR in Quito, Ecuador and an independent Principal Investigator in respect of many of the Company's clinical trials, will present the Generex Oral-lyn™ diabetes treatment paradigm at the 8th Ecuadorian Endocrinology Congress being held in Cuenca, Ecuador, May 17-19, 2006. Generex Oral-lyn, the Company's proprietary oral insulin spray product, is currently manufactured and available for commercial sale in Ecuador for the treatment of Type-1 and Type-2 diabetes.
Generex Oral-lyn is a safe, simple, fast, effective, and pain-free alternative to subcutaneous injections of prandial insulin. Human regular insulin in the Generex Oral-lyn liquid spray product is conveniently delivered to the membranes of the oral cavity by a simple asthma-like device with no pulmonary (lung) deposition. Dr. Guevara will describe how Generex Oral-lyn can play a vital role as an interventional pharmacologic agent to delay the onset or progression of diabetes and the complications associated with diabetes. The prospect of more precise blood glucose control offered by Generex Oral-lyn will give physicians a greater opportunity to satisfy "treat to target" benchmarks identified by the American Diabetes Association and similar organizations.
The Congress brings together more than 300 endocrinologists, diabetologists, internists, general medical practitioners, and nurses in the field of endocrinology including diabetes and pediatric and adolescent endocrinology, and includes participation by scientific opinion leaders from Ecuador, Argentina, Columbia, Chile, the United States, Mexico, and Uruguay. Participating companies include GlaxoSmithKline, Merck, Roche, and Eli Lilly.
The Congress is another opportunity for Generex and its Latin American joint venture partner, PharmaBRAND, S.A. (www.pharmabrand.com.ec), to showcase Generex Oral-lyn and to increase awareness in the local medical community about the use and benefits of this novel insulin delivery system. Generex Oral-lyn has been approved by the Ecuadorian Ministry of Public Health for the treatment of patients with Type-1 and Type-2 diabetes mellitus.
Generex Oral-lyn will be featured at PharmaBRAND's presentation booth at the Congress where sales agents, promotional materials, and the Generex Oral-lyn monograph will be available. In addition, in the evening of May 17, 2006, PharmaBRAND will host a Congress-related dinner for more than 40 members of The Endocrine Society of Ecuador at which the Generex Oral-lyn monograph will be distributed.
Diese News reißen einen ja förmlich vom Hocker ....
Welcher Rebound?Ist nur ne vorbörsliche Falle!
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,57 | |
| -1,63 | |
| +0,07 | |
| -0,95 | |
| -2,89 | |
| +8,33 | |
| -3,03 | |
| +1,18 | |
| 0,00 | |
| +0,64 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 207 | ||
| 113 | ||
| 99 | ||
| 87 | ||
| 79 | ||
| 63 | ||
| 55 | ||
| 42 | ||
| 35 | ||
| 29 |
